0.1.1 - ci-build

ScheduleOfActivityIG - Local Development build (v0.1.1). See the Directory of published versions

Table of Contents

..0 Table of Contents
...1 Home
...2 CDISC Operational Model (ODM)
...3 Developer Setup
...4 Study Design for H2Q-MC-LZZT
...5 Clinical Research Profile Backlog
...6 Artifacts Summary
....6.1 H2Q-MC-LZZT-ProtocolDesign
....6.2 H2Q-MC-LZZT Research Study
....6.3 H2Q-MC-LZZT Exclusion Criteria
....6.4 H2Q-MC-LZZT Inclusion Criteria
....6.5 ET-14
....6.6 RT-15
....6.7 Visit-1
....6.8 Visit-10
....6.9 Visit-11
....6.10 Visit-12
....6.11 Visit-13
....6.12 Visit-2
....6.13 Visit-3
....6.14 Visit-4
....6.15 Visit-5
....6.16 Visit-6
....6.17 Visit-7
....6.18 Visit-8
....6.19 Visit-9
....6.20 Eli Lilly and Company
....6.21 Samuel Home, M.D.
....6.22 ADAS-Cog
....6.23 Adverse events
....6.24 Ambulatory ECG placed
....6.25 Ambulatory ECG removed
....6.26 Apo E genotyping
....6.27 CIBIC+
....6.28 CT Scan
....6.29 Chest x-ray
....6.30 Concomitant Medications
....6.31 DAD
....6.32 ECG
....6.33 Habits - Alcohol
....6.34 Habits - Caffeine
....6.35 Habits - Smoking
....6.36 Hachinski 4
....6.37 Hemoglobin A1C
....6.38 Informed Consent
....6.39 Laboratory (Chem)
....6.40 Laboratory (Hemat)
....6.41 Laboratory (Urinalysis)
....6.42 MMSE 10-23
....6.43 Medical History
....6.44 Medications dispensed
....6.45 Medications returned
....6.46 NPI-X
....6.47 Patient number assigned
....6.48 Patient randomized
....6.49 Physical examination
....6.50 Placebo TTS test
....6.51 Plasma Specimen
....6.52 Study drug record
....6.53 TTS Acceptability Survey
....6.54 Visit Date
....6.55 Vital signs/Temperature
....6.56 ADAS-Cog-Observations
....6.57 Adverse events-Observations
....6.58 Ambulatory ECG placed-Observations
....6.59 Ambulatory ECG removed-Observations
....6.60 Apo E genotyping-Observations
....6.61 CIBIC+-Observations
....6.62 CT Scan-Observations
....6.63 Chest x-ray-Observations
....6.64 Concomitant Medications-Observations
....6.65 DAD-Observations
....6.66 ECG-Observations
....6.67 Habits-Observations
....6.68 Hachinski 4-Observations
....6.69 Hemoglobin A1C-Observations
....6.70 Informed Consent-Observations
....6.71 Laboratory (Chem/Hemat)-Observations
....6.72 Laboratory (Urinalysis)-Observations
....6.73 MMSE 10-23-Observations
....6.74 Medical History-Observations
....6.75 Medications dispensed-Observations
....6.76 Medications returned-Observations
....6.77 NPI-X-Observations
....6.78 Patient number assigned-Observations
....6.79 Patient randomized-Observations
....6.80 Physical examination-Observations
....6.81 Placebo TTS test-Observations
....6.82 Plasma Specimen-Observations
....6.83 Study drug record-Observations
....6.84 TTS Acceptability Survey-Observations
....6.85 Vital signs/Temperature-Observations
....6.86 Research Study Inclusion Exclusion
....6.87 SOA Arm Definition
....6.88 SOA Epoch Defintion
....6.89 SOA PlanDefinition
....6.90 SOA Planned Visit Definition
....6.91 SOA Protocol Plan Defintion
....6.92 SOA Planned Study Activity Definition
....6.93 SOA Study Defintion
....6.94 SOA Subject
....6.95 SOA Unplanned Visit Definition
....6.96 SOA Visit Plan Defintion
....6.97 ResearchStudy Arm
....6.98 Arm Status
....6.99 Planned Study Day of Visit
....6.100 Planned Study Day Window
....6.101 Planned Study Offset of Visit
....6.102 Planned Study Window of Visit
....6.103 Epoch Type
....6.104 Study Milestone
....6.105 Study Event OID
....6.106 Unplanned Study Visit Range
....6.107 Arm Status Value Set
....6.108 Epoch Type Value Set
....6.109 Study Milestone
....6.110 Vital Signs/Temperature
....6.111 Temperature Measurement
....6.112 Temperature Measurement - Observation
....6.113 Temperature-Observation
....6.114 Temperature-Observation
....6.115 VitalSigns-Observation
....6.116 Vitalsigns-HeartRate-Blood-Pressure